X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (249) 249
humans (229) 229
male (141) 141
female (137) 137
middle aged (117) 117
mixed dyslipidemia (111) 111
adult (77) 77
aged (74) 74
pharmacology & pharmacy (68) 68
cholesterol (64) 64
analysis (55) 55
risk factors (54) 54
lipids (53) 53
statins (51) 51
fenofibrate (49) 49
drug therapy, combination (47) 47
treatment outcome (47) 47
diabetes (45) 45
dyslipidemia (44) 44
dyslipidemias - drug therapy (44) 44
mixed hyperlipidemia (44) 44
risk (42) 42
triglycerides (42) 42
cardiovascular-disease (41) 41
hypolipidemic agents - therapeutic use (41) 41
metabolic syndrome (41) 41
endocrinology & metabolism (40) 40
atherosclerosis (38) 38
cardiac & cardiovascular systems (38) 38
research (37) 37
simvastatin (37) 37
triglycerides - blood (37) 37
fenofibrate - therapeutic use (34) 34
health aspects (34) 34
coronary-heart-disease (33) 33
medicine & public health (33) 33
cardiovascular disease (31) 31
double-blind method (31) 31
drug therapy (31) 31
atorvastatin (29) 29
density-lipoprotein cholesterol (29) 29
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (29) 29
therapy (29) 29
biomarkers - blood (28) 28
internal medicine (28) 28
low density lipoproteins (28) 28
prevalence (28) 28
care and treatment (27) 27
lipids - blood (27) 27
adolescent (26) 26
cholesterol, ldl - blood (26) 26
dyslipidemias - blood (26) 26
hyperlipidemia (26) 26
insulin-resistance (26) 26
medicine, general & internal (26) 26
animals (25) 25
cardiology (25) 25
young adult (25) 25
hypercholesterolemia (24) 24
mortality (24) 24
safety (24) 24
anticholesteremic agents - therapeutic use (23) 23
cardiovascular diseases (23) 23
disease (23) 23
fenofibric acid (23) 23
glucose (23) 23
hyperlipidemias - drug therapy (23) 23
hypolipidemic agents - adverse effects (23) 23
peripheral vascular disease (23) 23
type 2 diabetes (23) 23
type-2 diabetes-mellitus (23) 23
biochemistry & molecular biology (22) 22
body mass index (22) 22
cardiovascular (22) 22
insulin resistance (22) 22
nutrition & dietetics (22) 22
obesity (22) 22
time factors (22) 22
ezetimibe (21) 21
fibrates (21) 21
racially mixed people (21) 21
combined hyperlipidemia (20) 20
combination therapy (19) 19
medical research (19) 19
coronary-artery-disease (18) 18
fenofibrate - administration & dosage (18) 18
hypertension (18) 18
hypolipidemic agents - administration & dosage (18) 18
insulin (18) 18
niacin (18) 18
blood glucose - metabolism (17) 17
fenofibrate - adverse effects (17) 17
genetic aspects (17) 17
medicine, research & experimental (17) 17
nutritional and metabolic diseases (17) 17
randomized controlled-trial (17) 17
risk-factors (17) 17
studies (17) 17
cardiovascular diseases - prevention & control (16) 16
cholesterol - blood (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (334) 334
Spanish (13) 13
Czech (3) 3
Korean (2) 2
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1479 - 1489
Aim: To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and... 
type 2 diabetes | mixed dyslipidaemia | non‐HDL cholesterol | PCSK | PCSK9 | non-HDL cholesterol | METAANALYSIS | EFFICACY | CARDIOVASCULAR EVENTS | SAFETY | RISK | PCSK9 INHIBITOR EVOLOCUMAB | GENETIC-VARIANTS | DENSITY-LIPOPROTEIN CHOLESTEROL | ENDOCRINOLOGY & METABOLISM | POOLED ANALYSIS | AMG 145 | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dyslipidemias - drug therapy | Double-Blind Method | Drug Administration Schedule | Cholesterol, HDL - metabolism | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Proprotein Convertase 9 - metabolism | Anticholesteremic Agents - adverse effects | Diabetes Mellitus, Type 2 - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypoglycemic Agents - administration & dosage | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Lipid Metabolism - drug effects | Female | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Blood cholesterol | Analysis | Low density lipoproteins | Glycosylated hemoglobin | Apolipoproteins | Niacin | Trans fatty acids | Statins | Diabetes therapy | Lipoproteins (low density) | Diabetes mellitus | Dyslipidemia | Nicotinic acid | Subtilisin | Low density lipoprotein | Cholesterol | Apolipoprotein B | Fenofibrate | Kexin | Motivation | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density) | Index Medicus | Original
Journal Article
Journal Article
Journal Article
The American Journal of the Medical Sciences, ISSN 0002-9629, 09/2018, Volume 356, Issue 3, pp. 254 - 261
Policosanol is a mixture of long-chain alcohols isolated from sugar cane. This controlled, randomized clinical trial was designed to compare the efficacy and... 
Fenofibrate | Policosanol | Mixed dyslipidemia | Elderly | Index Medicus | Abridged Index Medicus
Journal Article
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, ISSN 0002-9629, 09/2018, Volume 356, Issue 3, pp. 254 - 261
Background: Policosanol is a mixture of long-chain alcohols isolated from sugar cane. This controlled, randomized clinical trial was designed to compare the... 
Fenofibrate | MEDICINE, GENERAL & INTERNAL | PLACEBO | CHOLESTEROL | RATS | RISK | Policosanol | Mixed dyslipidemia | II HYPERCHOLESTEROLEMIA | Elderly | STATINS | BEZAFIBRATE
Journal Article
Journal of Cardiology, ISSN 0914-5087, 09/2019, Volume 74, Issue 3, pp. 290 - 295
To investigate which metabolic factors increase the risk of incident diabetes (T2D) in statin-treated patients. A retrospective study conducted in Greece... 
Obesity | Diabetes | Mixed dyslipidemia | Statin | Prediabetes
Journal Article
Journal Article
Journal Article
Journal Article
BMC Medical Genetics, ISSN 1471-2350, 11/2018, Volume 19, Issue 1, pp. 205 - 205
BackgroundThe objective of this study was to examine individual and community factors that influence high-density lipoprotein cholesterol (HDL-C) dyslipidemia... 
HDL | RBP4 | SNP | Mixed model | Dyslipidemia | Genetics | Newfoundland | Associations | POPULATION | METABOLIC SYNDROME | REGULATORY SNP | RISK | BLOOD-PRESSURE | INSULIN-RESISTANCE | CHOLESTEROL LEVELS | GENETICS & HEREDITY | CARDIOVASCULAR-DISEASE | BINDING-PROTEIN 4 | Dyslipidemias - genetics | Prevalence | Humans | Middle Aged | Male | Newfoundland and Labrador - epidemiology | Founder Effect | Dyslipidemias - blood | Smoking - physiopathology | Adult | Female | Retinol-Binding Proteins, Plasma - metabolism | Odds Ratio | Body Mass Index | Promoter Regions, Genetic | Gene Expression | Genetic Association Studies | Risk Factors | Smoking - genetics | Reproductive Isolation | Dyslipidemias - epidemiology | 5' Untranslated Regions | Sex Factors | Cholesterol, HDL - blood | Cholesterol, HDL - deficiency | Models, Genetic | Polymorphism, Single Nucleotide | Retinol-Binding Proteins, Plasma - genetics | Dyslipidemias - physiopathology | Usage | Dyslipidemias | Genetic variation | Cholesterol, HDL | Mixed methods research | Genetic aspects | Research | Geography | Medical records | Lipids | Cardiovascular disease | Single-nucleotide polymorphism | Metabolic syndrome | Population genetics | Primary care | Cholesterol | Risk factors | Data bases | Confidence intervals | Proteins | Studies | Lipoproteins | Surveillance | Population | Insulin resistance | Lipid metabolism | Lipoproteins (high density) | Smoking | Index Medicus
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 05/2017, Volume 16, Issue 1, pp. 70 - 70
Background: Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may... 
Mixed dyslipidaemia | PCSK9 | ODYSSEY | Alirocumab | Diabetes | Non-HDL-C | CARDIAC & CARDIOVASCULAR SYSTEMS | AMERICAN-COLLEGE | NATIONAL-HEALTH | MONOCLONAL-ANTIBODY | GENETIC-VARIANTS | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | DISEASE | ENDOCRINOLOGY & METABOLISM | POOLED ANALYSIS | ASSOCIATION | Cholesterol - blood | Humans | Antibodies, Monoclonal - adverse effects | Clinical Protocols | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Biomarkers - blood | Proprotein Convertase 9 - immunology | Anticholesteremic Agents - adverse effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Anticholesteremic Agents - therapeutic use | Hyperlipoproteinemia Type V - drug therapy | Proprotein Convertase 9 - antagonists & inhibitors | Time Factors | Hyperlipoproteinemia Type V - diagnosis | Hyperlipoproteinemia Type V - complications | Research Design | Diabetes Mellitus, Type 2 - complications | Hyperlipoproteinemia Type V - blood | Lipoproteins (low density) | Therapy | Nicotinic acid | Dyslipidemia | Clinical trials | Lipids | Cardiovascular disease | Criteria | Design analysis | Density | Information dissemination | Risk factors | Recruitment | Alignment | Risk assessment | Safety engineering | Atherosclerosis | Secondary analysis | Safety | Lipoproteins (high density) | Statins | Effectiveness | Mortality | Diabetes mellitus | Health risks | Triglycerides | Subtilisin | Fatty acids | Low density lipoprotein | Patients | Cholesterol | Studies | Fenofibrate | Kexin | Inhibitors | Arteriosclerosis | Insulin resistance | Acute coronary syndromes | Cardiovascular diseases | Risk management | Index Medicus
Journal Article